NeoGenomics Inc (FRA:NG9)
€ 12.5 -0.4 (-3.1%) Market Cap: 1.57 Bil Enterprise Value: 1.78 Bil PE Ratio: 0 PB Ratio: 1.82 GF Score: 74/100

Q4 2018 Neogenomics Inc Earnings Call Transcript

Feb 19, 2019 / 01:30PM GMT
Release Date Price: €15.58 (+0.06%)
Operator

Good day, ladies and gentlemen, and welcome to this NeoGenomics Inc. Fourth Quarter and Full Year 2018 Financial Results Conference Call. As a reminder, today's meeting is being recorded. (Operator Instructions)

And now at this time, for opening remarks and introductions, I am pleased to turn the floor over to Mr. Doug VanOort. Please go ahead, sir.

Douglas M. VanOort;William Bishop Bonello
NeoGenomics, Inc. - Chairman & CEO;NeoGenomics, Inc. - Chief Strategy &

Thank you, Jim. Good morning, everyone. I'd like to welcome everyone to NeoGenomics' Fourth Quarter 2018 Conference Call. Joining me from our Fort Myers headquarters is Sharon Virag, our Chief Financial Officer; Rob Shovlin, President of our Clinical Services Division; George Cardoza, President of our Pharma Services Division; and Bill Bonello, Chief Strategy and Corporate Development Officer and Director of Investor Relations.

Before we begin our prepared remarks, Bill Bonello will read the standard language about forward-looking statements.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot